Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) announced a potential exclusive agency agreement for its core product TY-9591 with Sichuan Huicheng Pharmaceutical Co., Ltd. (Sichuan Huicheng), which is a wholly-owned subsidiary of Sichuan Huicheng [1] Group 1 - Sichuan Huicheng's board approved the potential agency agreement for TY-9591, which will allow Sichuan Huicheng to act as the exclusive agent in mainland China, excluding Hong Kong, Macau, Taiwan, and other overseas regions [1] - The initial milestone payment for this agreement could reach up to RMB 150 million [1] - The company is entering the commercialization phase for TY-9591, and if the agency arrangement is finalized, it will leverage Sichuan Huicheng's extensive sales and distribution network [1] Group 2 - Sichuan Huicheng is a mature pharmaceutical enterprise with a complete industry chain and rich experience in drug agency and sales in China [1] - The company believes that this arrangement will enhance the sales and revenue of TY-9591, accelerate market penetration, reduce costs associated with establishing new sales channels, and strengthen its brand image through collaboration with a well-known pharmaceutical company [1]

Group 1 - The State Council emphasizes increasing financial and fiscal support for the artificial intelligence (AI) sector, aiming for over 70% penetration of new intelligent terminals and agents by 2027 [2][3] - By 2030, AI is expected to significantly contribute to high-quality economic development, with over 90% penetration of new intelligent applications [2] - The government plans to enhance the legal and regulatory framework for AI, including risk management and investment exit mechanisms [2][4] Group 2 - The National Development and Reform Commission (NDRC) will coordinate efforts to implement the AI action plan, ensuring local adaptation and avoiding superficial compliance [4] - The NDRC aims to foster a complete AI application service chain and promote the development of intelligent native technologies and services [4] - The NDRC will also support open-source ecosystem development to enhance international influence [4] Group 3 - The National Energy Administration acknowledges that the rapid growth of electric vehicle and AI sectors is driving increased electricity demand, which is reshaping energy consumption patterns [5][6] - Data indicates a 34.3% year-on-year increase in electricity consumption for new energy vehicle manufacturing in 2024, and a 20.5% increase for internet and related services [5][6] Group 4 - The new generation of the Chinese operating system, Galaxy Kirin V11, has been officially released, featuring significant improvements in architecture, security, and ecosystem compatibility [6] - Galaxy Kirin has achieved over 16 million deployments and is compatible with major domestic CPUs and GPUs, supporting various national projects [6] Group 5 - ByteDance has raised its option price to $200.41 per share, marking a significant increase from $189.9 earlier this year, reflecting a fivefold increase since 2019 [6] Group 6 - Aliyun's Baolian has announced a price reduction for certain model context caching, lowering the cost from 40% to 20% of the input token price when cache hits occur [7] Group 7 - Union Medical has received a medical device registration certificate for China's first photon counting spectral CT, marking a significant advancement in medical technology [8] - Nanjing New Pharmaceutical plans to acquire assets from Future Medicine for up to 480 million yuan, which is expected to constitute a major asset restructuring [9] - Biyimi plans to acquire 100% of Shanghai Xingan Semiconductor for 295 million yuan to enhance its core business and technology capabilities [10]

Core Viewpoint - The announcement indicates that Sichuan Huiyu Pharmaceutical Co., Ltd. has approved a potential agency agreement for the core product TY-9591, which could enhance sales and market penetration in China [1] Group 1: Agreement Details - Sichuan Huichen Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sichuan Huiyu, may be appointed as the exclusive agent for TY-9591 in mainland China, with an initial milestone payment of up to RMB 150 million [1] - The potential agency arrangement is aimed at leveraging the existing sales and distribution network of Sichuan Huichen and Sichuan Huiyu [1] Group 2: Strategic Implications - The arrangement is expected to accelerate market penetration and reduce costs associated with establishing new sales channels for TY-9591 [1] - Collaborating with a well-established pharmaceutical company like Sichuan Huiyu is anticipated to strengthen the company's brand image in the market [1]

一、 监事会会议召开情况 四川汇宇制药股份有限公司（以下简称"公司"或"汇宇制药"）第二届监 事会第十七次会议于 2025 年 8 月 25 日以通讯表决方式召开，会议通知已于 2025 年 8 月 22 日以电子邮件方式发出通知，经全体监事一致同意，本次会议豁免通 知期限。本次会议由公司监事会主席邓玲女士召集并主持，应出席监事 3 人，实 际出席监事 3 人。全体监事认可本次会议的通知时间、议案内容等事项，本次监 事会的召集和召开程序符合《中华人民共和国公司法》《中华人民共和国证券法》 等法律法规及《公司章程》的相关规定，会议决议合法有效。 二、监事会会议审议情况 （一）审议通过《关于拟签署<同源康"TY-9591"产品的全国总代理协议> 暨关联交易的议案》 经与会监事认真审议，公司本次关联交易为公司正常经营和业务发展需要， 关联交易定价依据公平、合理，没有违反公开、公平、公正的原则，不存在损害 公司和中小股东的利益行为，不会对公司独立性产生影响，公司主营业务不会因 此类交易而对关联方形成依赖，其审议和决策程序符合相关法律法规的规定。 证券代码：688553 证券简称：汇宇制药 公告编号：2025-062 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-061 四川汇宇制药股份有限公司 董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 四川汇宇制药股份有限公司（以下简称"公司""汇宇制药"）第二届董事会 第十七次会议于 2025 年 8 月 25 日以通讯方式在公司会议室召开。会议通知和会 议资料已于 2025 年 8 月 22 日以电子邮件方式发出，经全体董事一致同意，本次 会议豁免通知期限。本次会议由董事长丁兆先生主持，会议应出席董事 8 人，实 际出席董事 8 人，相关监事及高管列席。全体董事一致同意并认可本次会议的通 知和召开时间、议案内容等事项，本次董事会会议的召集和召开程序符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》的规定，作出的决议合法、 有效。 二、董事会会议审议情况 （一）审议通过《关于拟签署<同源康"TY-9591"产品的全国总代理协议> 暨关联交易的议案》 表决结果：8 票赞成；0 票弃权；0 票反对。 特此公告。 四川汇宇制药股份有 ...

第三次会议决议 第二届董事会独立董事专门会议 四川汇宇制药股份有限公司 表决结果:同意3 票,反对 0 票,弃权 0 票。 四川汇宇制药股份有限公司 独立董事:龙永强、梁昕昕、谭勇 2025年8月25日 [本页无正文,为四川汇宇制药股份有限公司第二届董事会独立董事专门会议第 三次会议决议签署页] 全体独立董事对本次会议议案进行了审议,以记名投票表决方式,通过如下 决议: 一、审议通过《关于拟签署<同源康"TY-9591"产品的全国总代理协议>暨 关联交易的议案》 本次关联交易为公司正常的业务需要,属于公司正常经营和业务发展需要, 有利于公司的长远发展,符合公司的整体战略规划,也符合公司以及全体股东的 利益。标的资产权属清晰,定价公允且合理,不存在损害公司和中小股东利益的 情形,不会对公司财务及经营情况产生不利影响,不会影响公司独立性。因此, 我们一致同意本次关联交易事项,并同意将该事项提交公司董事会审议。 四川汇宇制药股份有限公司(以下简称"公司")第二届董事会独立董事专 门会议第三次会议于 2025年 8 月 25 日以通讯方式召开。本次会议由全体独立董 事共同推举龙永强先生担任会议召集人并主持本次会议,会 ...

Group 1 - The board of directors of Sichuan Huiyu Pharmaceutical Co., Ltd. held its 17th meeting on August 25, 2025, via telecommunication, with all 8 directors present and unanimously agreeing on the meeting's agenda and procedures [1][2] - The board approved the proposal to sign a national general agency agreement for the product "TY-9591," with a voting result of 7 votes in favor, 0 abstentions, and 0 against [1][2] - The board also decided not to convene a shareholders' meeting to review the related matters at this time, with a voting result of 8 votes in favor, 0 abstentions, and 0 against [2]

证券代码：688553 证券简称：汇宇制药 公告编号：2025-062 四川汇宇制药股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 四川汇宇制药股份有限公司（以下简称"公司"或"汇宇制药"）第二届监 事会第十七次会议于 2025 年 8 月 25 日以通讯表决方式召开，会议通知已于 2025 年 8 月 22 日以电子邮件方式发出通知，经全体监事一致同意，本次会议豁免通 知期限。本次会议由公司监事会主席邓玲女士召集并主持，应出席监事 3 人，实 际出席监事 3 人。全体监事认可本次会议的通知时间、议案内容等事项，本次监 事会的召集和召开程序符合《中华人民共和国公司法》 《中华人民共和国证券法》 等法律法规及《公司章程》的相关规定，会议决议合法有效。 监事会 （一）审议通过《关于拟签署 <同源康 ty-9591="TY-9591" 产品的全国总代理协议="产品的全国总代 理协议"> 暨关联交易的议案》 经与会监事认真审议，公司本次关联交易为公司正常经营和业务发展需要， 关联交易定价依据 ...

本次交易未构成重大资产重组。 证券代码：688553 证券简称：汇宇制药 公告编号：2025-063 四川汇宇制药股份有限公司 关于拟签署全国总代理协议暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 关联交易内容：四川汇宇制药股份有限公司（以下简称"公司"）全 资子公司四川汇辰昕药业有限公司（以下简称"汇辰昕"）拟与浙江同源康医 药股份有限公司（以下简称"同源康"）签署《关于同源康"TY-9591"产品的 全国总代理协议》（以下简称"总代理协议"），同源康同意将其"TY-9591"产 品的全国总代理权授权给汇辰昕，"TY-9591"产品的全国总代理的区域范围是： 中国大陆地区，不包括港澳台及境外其他国家/地区的市场。 交易金额：里程碑首付款为 15,000 万元人民币（里程碑总金额及首 付款支付方式双方另行协商约定）。 关联关系：同源康系公司实际控制人、董事长丁兆曾担任董事的企 业。2025 年 3 月丁兆因个人原因辞任董事职务，根据《上市规则》第 15.1 条 第（十五）项的有关规定，同 ...

Core Insights - The company Huayu Pharmaceutical announced that its wholly-owned subsidiary Huichenxing plans to sign a national general agency agreement with Tongyuan Kang for the product "TY-9591" [1] - Tongyuan Kang has agreed to grant the national agency rights for "TY-9591" to Huichenxing, with a milestone upfront payment of 150 million RMB [1] - "TY-9591" is an orally administered, irreversible third-generation EGFR (epidermal growth factor receptor) inhibitor developed independently by Tongyuan Kang [1]